source
- FDA approves Lilly's new combination therapy for advanced breast cancerThe U.S. Food and Drug Administration has granted approval for a new combination drug regimen developed by Eli Lilly for patients with an advanced form of breast cancer. The therapy pairs two agen…
- Novo Nordisk vows to launch five multi-blockbuster drugs by 2030 as it shifts toward consumer-style productsNovo Nordisk used its London capital markets day to reassure investors that the company will broaden its pipeline and market new medicines more like consumer products than traditional drugs. The C…